Table 1.
Prediction of treatment outcome from the three baseline symptom dimensions in GENDEP
| Overall |
Escitalopram |
Nortriptyline |
Interaction with drug |
|||||
|---|---|---|---|---|---|---|---|---|
| (n=811) |
(n=457) |
(n=354) |
(n=811) |
|||||
| Predictor | β (95% CI) | p | β (95% CI) | p | β (95% CI) | p | β (95% CI) | p |
| (1) Outcome: MADRS | ||||||||
| Observed mood | 0.11 (0.02 to 0.18) | 0.0134 | 0.13 (0.02 to 0.23) | 0.0236 | 0.08 (−0.05 to 0.19) | 0.2338 | 0.00 (−0.09 to 0.07) | 0.8468 |
| Cognitive | 0.14 (0.09 to 0.19) | 5.2×10−8 | 0.15 (0.08 to 0.21) | 3.3×10−5 | 0.13 (0.05 to 0.19) | 0.0013 | −0.01 (−0.10 to 0.05) | 0.5394 |
| Neurovegetative | 0.00 (−0.05 to 0.05) | 0.9730 | 0.00 (−0.07 to 0.07) | 0.9541 | 0.00 (−0.07 to 0.08) | 0.9728 | 0.00 (−0.08 to 0.08) | 0.9293 |
| (2) Outcome: HAMD-17 | ||||||||
| Observed mood | 0.15 (0.08 to 0.20) | 2.5×10−6 | 0.15 (0.06 to 0.22) | 0.0004 | 0.14 (0.04 to 0.21) | 0.0042 | 0.00 (−0.08 to 0.08) | 0.9787 |
| Cognitive | 0.14 (0.08 to 0.18) | 2.2×10−8 | 0.14 (0.07 to 0.20) | 1.9×10−5 | 0.12 (0.04 to 0.18) | 0.0015 | −0.01 (−0.10 to 0.05) | 0.5501 |
| Neurovegetative | 0.00 (−0.05 to 0.05) | 0.9936 | 0.01 (−0.06 to 0.08) | 0.8063 | −0.01 (−0.09 to 0.06) | 0.7328 | −0.01 (−0.10 to 0.06) | 0.6731 |
| (3) Outcome: BDI | ||||||||
| Observed mood | 0.12 (0.07 to 0.16) | 2.3×10−6 | 0.12 (0.05 to 0.18) | 0.0006 | 0.13 (0.05 to 0.19) | 0.0006 | 0.00 (−0.09 to 0.07) | 0.8439 |
| Cognitive | 0.05 (−0.05 to 0.15) | 0.3090 | 0.04 (−0.09 to 0.17) | 0.5450 | 0.05 (−0.09 to 0.19) | 0.5131 | −0.01 (−0.11 to 0.06) | 0.5903 |
| Neurovegetative | −0.01 (−0.06 to 0.04) | 0.6433 | −0.01 (−0.07 to 0.06) | 0.8245 | −0.01 (−0.08 to 0.06) | 0.7910 | −0.01 (−0.10 to 0.07) | 0.6667 |
GENDEP, Genome-based Therapeutic Drugs for Depression ; CI, confidence interval ; MADRS, Montgomery–Åsberg Depression Rating Scale ; HAMD-17, 17-item Hamilton Depression Rating Scale ; BDI, Beck Depression Inventory.
The table shows results for the primary clinician-rated outcome (MADRS), secondary clinician-rated outcome (HAMD-17) and secondary self-report outcome (BDI). Standardized estimates (β), 95% CIs and uncorrected probability of results occurring by chance (p) are based on mixed-effect linear regression models with baseline score on the outcome measure entered as a covariate of no interest (e.g. for all analyses using MADRS as the outcome, MADRS score at baseline was entered as a covariate). β can be interpreted as the effect size. Negative values of β indicate better treatment outcome, positive values of β reflect worse treatment outcome.
p values <0.05 are highlighted in bold to indicate nominal statistical significance.